LU503660B1 - METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS AND APPLICATION THEREOF - Google Patents
METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS AND APPLICATION THEREOF Download PDFInfo
- Publication number
- LU503660B1 LU503660B1 LU503660A LU503660A LU503660B1 LU 503660 B1 LU503660 B1 LU 503660B1 LU 503660 A LU503660 A LU 503660A LU 503660 A LU503660 A LU 503660A LU 503660 B1 LU503660 B1 LU 503660B1
- Authority
- LU
- Luxembourg
- Prior art keywords
- anhydride
- quercetin
- chloride
- ester
- pot
- Prior art date
Links
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 title claims abstract description 131
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 title claims abstract description 80
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 title claims abstract description 80
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title claims abstract description 80
- 235000005875 quercetin Nutrition 0.000 title claims abstract description 80
- 229960001285 quercetin Drugs 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 24
- 238000005580 one pot reaction Methods 0.000 title claims abstract description 23
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 14
- -1 quercetin ester Chemical class 0.000 claims abstract description 64
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 32
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 32
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 32
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract description 32
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 32
- 235000005493 rutin Nutrition 0.000 claims abstract description 32
- 229960004555 rutoside Drugs 0.000 claims abstract description 32
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 23
- 239000002253 acid Substances 0.000 claims abstract description 14
- 150000001263 acyl chlorides Chemical class 0.000 claims abstract description 13
- 150000008064 anhydrides Chemical class 0.000 claims abstract description 11
- 239000003513 alkali Substances 0.000 claims abstract description 8
- 230000009471 action Effects 0.000 claims abstract description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 28
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical group CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 9
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 6
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 claims description 4
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 claims description 4
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 4
- 238000009835 boiling Methods 0.000 claims description 4
- YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 claims description 3
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 claims description 3
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001209 o-nitrophenyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])[N+]([O-])=O 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 claims description 3
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- OLENANGIJWDOPG-UHFFFAOYSA-N (2-chlorobenzoyl) 2-chlorobenzoate Chemical compound ClC1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1Cl OLENANGIJWDOPG-UHFFFAOYSA-N 0.000 claims description 2
- YLBSXJWDERHYFY-UHFFFAOYSA-N (2-methylbenzoyl) 2-methylbenzoate Chemical compound CC1=CC=CC=C1C(=O)OC(=O)C1=CC=CC=C1C YLBSXJWDERHYFY-UHFFFAOYSA-N 0.000 claims description 2
- JAUFWTSSYRTLLB-UHFFFAOYSA-N (2-phenylacetyl) 2-phenylacetate Chemical compound C=1C=CC=CC=1CC(=O)OC(=O)CC1=CC=CC=C1 JAUFWTSSYRTLLB-UHFFFAOYSA-N 0.000 claims description 2
- MWUSAETYTBNPDG-UHFFFAOYSA-N (4-chlorobenzoyl) 4-chlorobenzoate Chemical compound C1=CC(Cl)=CC=C1C(=O)OC(=O)C1=CC=C(Cl)C=C1 MWUSAETYTBNPDG-UHFFFAOYSA-N 0.000 claims description 2
- BJMLLSSSTGHJJE-UHFFFAOYSA-N (4-methylbenzoyl) 4-methylbenzoate Chemical compound C1=CC(C)=CC=C1C(=O)OC(=O)C1=CC=C(C)C=C1 BJMLLSSSTGHJJE-UHFFFAOYSA-N 0.000 claims description 2
- NOGFHTGYPKWWRX-UHFFFAOYSA-N 2,2,6,6-tetramethyloxan-4-one Chemical group CC1(C)CC(=O)CC(C)(C)O1 NOGFHTGYPKWWRX-UHFFFAOYSA-N 0.000 claims description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 239000012346 acetyl chloride Substances 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- 229940014800 succinic anhydride Drugs 0.000 claims description 2
- RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 claims 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 1
- 101100532679 Caenorhabditis elegans scc-1 gene Proteins 0.000 claims 1
- 101150065749 Churc1 gene Proteins 0.000 claims 1
- 102100038239 Protein Churchill Human genes 0.000 claims 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 claims 1
- 239000001117 sulphuric acid Substances 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 150000003244 quercetin derivatives Chemical class 0.000 abstract description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 66
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 239000002244 precipitate Substances 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- JQUHMSXLZZWRHU-UHFFFAOYSA-N [2-acetyloxy-4-(3,5,7-triacetyloxy-4-oxochromen-2-yl)phenyl] acetate Chemical compound C=1C(OC(=O)C)=CC(OC(C)=O)=C(C(C=2OC(C)=O)=O)C=1OC=2C1=CC=C(OC(C)=O)C(OC(C)=O)=C1 JQUHMSXLZZWRHU-UHFFFAOYSA-N 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 17
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 description 17
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012153 distilled water Substances 0.000 description 13
- 238000010992 reflux Methods 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 12
- 238000002390 rotary evaporation Methods 0.000 description 11
- 239000003480 eluent Substances 0.000 description 10
- 230000007935 neutral effect Effects 0.000 description 10
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000009210 therapy by ultrasound Methods 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- IONYGGJUUJFXJK-UHFFFAOYSA-N 2,3,4,5,6-pentachlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IONYGGJUUJFXJK-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 4
- 229930020125 aflatoxin-B1 Natural products 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 101100449517 Arabidopsis thaliana GRH1 gene Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 101100434479 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) AFB1 gene Proteins 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 231100000025 genetic toxicology Toxicity 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N propyl acetate Chemical compound CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 2
- 150000003243 quercetin Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- JKVBWACRUUUEAR-UHFFFAOYSA-N (4-chlorophenyl)sulfanyl-(2,4,5-trichlorophenyl)diazene Chemical compound C1=CC(Cl)=CC=C1SN=NC1=CC(Cl)=C(Cl)C=C1Cl JKVBWACRUUUEAR-UHFFFAOYSA-N 0.000 description 1
- QAOJBHRZQQDFHA-UHFFFAOYSA-N 2,3-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Cl QAOJBHRZQQDFHA-UHFFFAOYSA-N 0.000 description 1
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 description 1
- VPHHJAOJUJHJKD-UHFFFAOYSA-N 3,4-dichlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-N 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- ZJIOBDJEKDUUCI-UHFFFAOYSA-N 3,5-dimethylbenzoyl chloride Chemical compound CC1=CC(C)=CC(C(Cl)=O)=C1 ZJIOBDJEKDUUCI-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- AVTLLLZVYYPGFX-UHFFFAOYSA-N 4-ethylbenzoyl chloride Chemical compound CCC1=CC=C(C(Cl)=O)C=C1 AVTLLLZVYYPGFX-UHFFFAOYSA-N 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 description 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010025654 Malignant melanoma of sites other than skin Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000002115 aflatoxin B1 Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 229940125648 antineoplastic drug candidate Drugs 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- RDZGDBJFHDKEDD-UHFFFAOYSA-N dcho Chemical compound C1C2=CC=CCC2=C2OC2=C2CC=CC=C21 RDZGDBJFHDKEDD-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000007674 genetic toxicity Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical class O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 125000001874 trioxidanyl group Chemical group [*]OOO[H] 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention belongs to the technical field of chemical synthesis, and in particular relates to a method for synthesizing quercetin ester by one-pot, products and applications thereof. Rutin is reacted with anhydride or acyl chloride, boiled in one pot under the action of acid or alkali, and then directly prepared into quercetin ester by ultrasonic at the power of 300W for 50min. The invention provides a plurality of new quercetin ester compounds which are synthesized by a one-pot method. The method has the advantages of easily available reagents, mild conditions, few operation steps, labor and time saving, raw materials saving, less emission pollution and high yield, which lays a foundation for the effective utilization of quercetin derivatives and has popularization value.The invention belongs to the technical field of chemical synthesis, and in particular relates to a method for synthesizing quercetin ester by one-pot, products and applications thereof. Rutin is reacted with anhydride or acyl chloride, boiled in one pot under the action of acid or alkali, and then directly prepared into quercetin ester by ultrasonic at the power of 300W for 50min. The invention provides a plurality of new quercetin ester compounds which are synthesized by a one-pot method. The method has the advantages of easily available reagents, mild conditions, few operation steps, labor and time saving, raw materials saving, less emission pollution and high yield, which lays a foundation for the effective utilization of quercetin derivatives and has popularization value.
Description
DESCRIPTION LU503660DESCRIPTION LU503660
METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTSMETHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS
AND APPLICATION THEREOFAND APPLICATION THEREOF
The invention belongs to the technical field of chemical synthesis, and in particular relates to a method for synthesizing quercetin ester by one-pot, products and applications thereof.The invention belongs to the technical field of chemical synthesis, and in particular relates to a method for synthesizing quercetin ester by one-pot, products and applications thereof.
Quercetin (3,4',3',5,7- pentahydroxyflavone) is a typical flavonoid, which exists in many foods such as apples, onions, broccoli, grapes, ginkgo biloba, tea and so on.Quercetin (3,4',3',5,7- pentahydroxyflavone) is a typical flavonoid, which exists in many foods such as apples, onions, broccoli, grapes, ginkgo biloba, tea and so on.
Quercetin has many physiological activities, such as anti-cancer, blood-lowering, anti-virus, prevention and treatment of cardiovascular and cerebrovascular diseases, anti-inflammatory and anti-oxidation. Epidemiologists and nutritionists believe that quercetin is a natural compound with the most promising application in the prevention and treatment of diseases. The molecular structure of quercetin makes it poor in water solubility and low in bioavailability. In order to improve this situation, many quercetin metal complexes and quercetin esters with good water solubility and high bioavailability have been prepared. For example, quercetin glutamic acid and quercetin alanine ester were synthesized by Tahsin, which can be used as the most effective conjugate to inhibit cell growth and have a good inhibitory effect on prostate cancer cells (TAHSIN F K,Quercetin has many physiological activities, such as anti-cancer, blood-lowering, anti-virus, prevention and treatment of cardiovascular and cerebrovascular diseases, anti-inflammatory and anti-oxidation. Epidemiologists and nutritionists believe that quercetin is a natural compound with the most promising application in the prevention and treatment of diseases. The molecular structure of quercetin makes it poor in water solubility and low in bioavailability. In order to improve this situation, many quercetin metal complexes and quercetin esters with good water solubility and high bioavailability have been prepared. For example, quercetin glutamic acid and quercetin alanine ester were synthesized by Tahsin, which can be used as the most effective conjugate to inhibit cell growth and have a good inhibitory effect on prostate cancer cells (TAHSIN F K,
MARIA V C, MIN-SUNG L E, et al. Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL[J].MARIA V C, MIN-SUNG L E, et al. Rational design and structure-activity relationship studies of quercetin-amino acid hybrids targeting the anti-apoptotic protein Bcl-xL[J].
Org. Biomol. Chem., 2017, 15(37): 7956-7976.). Quercetin -3-O- phenyl isocyanate was synthesized by Ye Bin et al. It has good inhibitory effects on human chronic bone marrow leukemia cell K562(/Cs50=1.852umol/L) and mouse colon cancer cellOrg. Biomol. Chem., 2017, 15(37): 7956-7976.). Quercetin -3-O- phenyl isocyanate was synthesized by Ye Bin et al. It has good inhibitory effects on human chronic bone marrow leukemia cell K562(/Cs50=1.852umol/L) and mouse colon cancer cell
CT26(/Cs0=1.177pmol/L), which are 73 times and 308 times higher than quercetihJ503660 respectively (YE Bin, YANG Jin-liang, CHEN Li-juan, et al. Induction of apoptosis by phenylisocyanate derivative of quercetin: involvement of heat shock protein[J].CT26(/Cs0=1.177pmol/L), which are 73 times and 308 times higher than quercetihJ503660 respectively (YE Bin, YANG Jin-liang, CHEN Li-juan, et al. Induction of apoptosis by phenylisocyanate derivative of quercetin: involvement of heat shock protein[J].
Anti-Cancer Drugs, 2007, 18 (10): 1165-1171.). Hirpara, Ketan V. Studies show that molecules from plants play an important role in cancer chemotherapy. Flavonoid quercetin, a plant-derived molecule, has been shown to regulate proliferation and cause cancer cell death. Some flavonoids have entered clinical trials, among which quercetin has emerged as a prospective anticancer drug candidate, and its prodrug quercetin -3- amino acid ester (QC12) has entered phase | clinical research (Hirpara, Ketan V.;Anti-Cancer Drugs, 2007, 18 (10): 1165-1171.). Hirpara, Ketan V. Studies show that molecules from plants play an important role in cancer chemotherapy. Flavonoid quercetin, a plant-derived molecule, has been shown to regulate proliferation and cause cancer cell death. Some flavonoids have entered clinical trials, among which quercetin has emerged as a prospective anticancer drug candidate, and its prodrug quercetin -3- amino acid ester (QC12) has entered phase | clinical research (Hirpara, Ketan V.;
Aggarwal, Pawan; Mukherjee, Amrita J.;et al. Quercetin and Its Derivatives: Synthesis,Aggarwal, Pawan; Mukherjee, Amrita J.; et al. Quercetin and Its Derivatives: Synthesis,
Pharmacological Uses with Special Emphasis on Anti-Tumor Properties and Prodrug with Enhanced Bio-Availability, Anti-Cancer Agents in Medicinal Chemistry (FormerlyPharmacological Uses with Special Emphasis on Anti-Tumor Properties and Prodrug with Enhanced Bio-Availability, Anti-Cancer Agents in Medicinal Chemistry (Formerly
Current Medicinal Chemistry - Anti-Cancer Agents), 2009 ,9(2): 138-161.). Ekta Kohli and other experiments found that quercetin pentaacetate (QPA) can inhibit the genotoxicity of aflatoxin B1(AFB1). The function of QPA leads to the regulation of some enzymes (such as P-450 enzyme, catalytic activity of NADPH) through microsomal transacetylase, and cytochrome C reductase and glutathione S- transferase may be acetylated through protein. Unlike quercetin, QPA can be observed to inhibit the binding of AFB1 to DNA. Explain the role of QPA in preventing genetic toxicity caused by AFB1 (Ekta Kohli, Hanumantharao G. Raj, Ranju Kumari, et al. Comparison of the Prevention of Aflatoxin B1-Induced Genotoxicity by Quercetin and Quercetin Pentaacetate,Current Medicinal Chemistry - Anti-Cancer Agents), 2009, 9(2): 138-161.). Ekta Kohli and other experiments found that quercetin pentaacetate (QPA) can inhibit the genotoxicity of aflatoxin B1(AFB1). The function of QPA leads to the regulation of some enzymes (such as P-450 enzyme, catalytic activity of NADPH) through microsomal transacetylase, and cytochrome C reductase and glutathione S-transferase may be acetylated through protein. Unlike quercetin, QPA can be observed to inhibit the binding of AFB1 to DNA. Explain the role of QPA in preventing genetic toxicity caused by AFB1 (Ekta Kohli, Hanumantharao G. Raj, Ranju Kumari, et al. Comparison of the Prevention of Aflatoxin B1-Induced Genotoxicity by Quercetin and Quercetin Pentaacetate,
Bioorganic & Medicinal Chemistry Letters 2002,12 : 2579-2582). ZHANG Yihua et al. synthesized 3, 3', 4', 5- tetra -O- acylated quercetin, and synthesized 3, 3', 4', 5- tetra -O- acetylated quercetin and 3, 3', 4', 5- tetra -O- propionylated quercetin respectively (CN 105693677 A, Application date: 2016.03.01).Bioorganic & Medicinal Chemistry Letters 2002,12:2579-2582). ZHANG Yihua et al. synthesized 3, 3', 4', 5- tetra -O- acylated quercetin, and synthesized 3, 3', 4', 5- tetra -O- acetylated quercetin and 3, 3', 4', 5- tetra -O - propionylated quercetin respectively (CN 105693677 A, Application date: 2016.03.01).
Quercetin esters have good pharmacological activities, some of which have significant inhibitory effects on cancer cells, while others have strong free radical scavenging ability, which provides important clues for the effective utilization of natural compounds. There are many reports on quercetin monoacyl ester compounds, but few on quercetin diacyl ester compounds, quercetin triacyl ester compounds and quercetin tetraacyl ester compounds. At present, only quercetin pentaacetate is reported drJ503660 quercetin pentaacyl ester compounds. In addition, the conventional method of synthesizing quercetin ester is as follows: rutin is hydrolyzed in methanol hydrochloric acid solution, and quercetin is obtained by separation. Quercetin is esterified with anhydride or acyl chloride under the action of concentrated sulfuric acid to obtain quercetin ester.Quercetin esters have good pharmacological activities, some of which have significant inhibitory effects on cancer cells, while others have strong free radical scavenging ability, which provides important clues for the effective utilization of natural compounds. There are many reports on quercetin monoacyl ester compounds, but few on quercetin diacyl ester compounds, quercetin triacyl ester compounds and quercetin tetraacyl ester compounds. At present, only quercetin pentaacetate is reported drJ503660 quercetin pentaacyl ester compounds. In addition, the conventional method of synthesizing quercetin ester is as follows: rutin is hydrolyzed in methanol hydrochloric acid solution, and quercetin is obtained by separation. Quercetin is esterified with anhydride or acyl chloride under the action of concentrated sulfuric acid to obtain quercetin ester.
LAOH es 0LAOH es 0
HO LA x A ~, & 2 Je HO. I LA, PX 8 H | ET Toe CHOR, HO . RC [ § | Oo © SE So. = I CE OHHO LA x A ~, & 2 I HO. I THE, PX 8 H | AND Toe CHOR, HO. CR [ § | Oo © SE So. = I CE OH
Au 3 “Ruin sugar nu àAt 3 “Ruin sugar naked at
ROCO. LA 102 8 AROCO. LA 102 8 A
Sn Np” eT he FT TN ym a (RODS RCOCH . HST \ | | OCORSn Np” eT he FT TN ym a (RODS RCOCH . HST \ | | OCOR
EEE nu bee, ab ALEEE nu bee, ab AL
FAN YT Y CORFAN YT Y COR
ROGO DROGO D
The disadvantages of this method are that the hydrolysis of rutin needs to consume a lot of methanol, and it is difficult to separate methanol from water to form an azeotrope, and the discharge of acid-containing wastewater seriously pollutes the environment. The cost of products obtained by rutin hydrolysis and quercetin esterification is relatively high.The disadvantages of this method are that the hydrolysis of rutin needs to consume a lot of methanol, and it is difficult to separate methanol from water to form an azeotrope, and the discharge of acid-containing wastewater seriously pollutes the environment. The cost of products obtained by rutin hydrolysis and quercetin esterification is relatively high.
SUMMARY LU503660SUMMARY LU503660
The purpose of the invention is to provide a method for synthesizing quercetin ester by one-pot, its product and application.The purpose of the invention is to provide a method for synthesizing quercetin ester by one-pot, its product and application.
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
The invention relates to a method for synthesizing quercetin ester by one-pot boiling, which comprises the following steps: reacting rutin with anhydride or acyl chloride, boiling in one pot under the action of acid or alkali, and then directly preparing quercetin ester by ultrasonic at the power of 300W for 50 minutes; the general structural formula of the quercetin ester is as follows: where the R substituents can be the same or different from the following substituents: methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tert-butyl, phenyl, benzyl, o-methylphenyl, m-methylphenyl, p-methylphenyl, o-ethylphenyl, m-ethylphenyl, p-ethylphenyl, o-nitrophenyl, m-hydroxyphenyl, p-chlorophenyl, p-bromophenyl, 2,3-dichlorophenyl, 3,5-dichlorophenyl.The invention relates to a method for synthesizing quercetin ester by one-pot boiling, which includes the following steps: reacting rutin with anhydride or acyl chloride, boiling in one pot under the action of acid or alkali, and then directly preparing quercetin ester by ultrasonic at the power of 300W for 50 minutes; the general structural formula of the quercetin ester is as follows: where the R substituents can be the same or different from the following substituents: methyl, ethyl, propyl, butyl, isopropyl, isobutyl, tert-butyl, phenyl, benzyl, o-methylphenyl , m-methylphenyl, p-methylphenyl, o-ethylphenyl, m-ethylphenyl, p-ethylphenyl, o-nitrophenyl, m-hydroxyphenyl, p-chlorophenyl, p-bromophenyl, 2,3-dichlorophenyl, 3,5-dichlorophenyl.
The acid anhydride is aliphatic acid anhydride or aromatic acid anhydride.The acid anhydride is aliphatic acid anhydride or aromatic acid anhydride.
The aliphatic anhydride can be acetic anhydride, propionic anhydride, butyric anhydride, succinic anhydride or butyric anhydride; The aromatic anhydride is benzoic anhydride, phenylacetic anhydride, o-methylbenzoic anhydride, p-methylbenzoic anhydride, o-chlorobenzoic anhydride or p-chlorobenzoic anhydride.The aliphatic anhydride can be acetic anhydride, propionic anhydride, butyric anhydride, succinic anhydride or butyric anhydride; The aromatic anhydride is benzoic anhydride, phenylacetic anhydride, o-methylbenzoic anhydride, p-methylbenzoic anhydride, o-chlorobenzoic anhydride or p-chlorobenzoic anhydride.
The acyl chloride is preferably selected from one of the following: acetyl chloride, propionyl chloride, butyryl chloride, benzoyl chloride, phenylacetyl chloride, o-methylbenzoyl chloride, m-methylbenzoyl chloride, p-methylbenzoyl chloride, and o-chlorobenzoyl chloride.The acyl chloride is preferably selected from one of the following: acetyl chloride, propionyl chloride, butyryl chloride, benzoyl chloride, phenylacetyl chloride, o-methylbenzoyl chloride, m-methylbenzoyl chloride, p-methylbenzoyl chloride, and o-chlorobenzoyl chloride.
The acid is sulfuric acid and hydrochloric acid, and the base is aniline, piperidine 6503660 pyridine. Generally, acid is used as catalyst for the reaction of rutin with acid anhydride, and alkali is used as catalyst for the reaction of rutin with acyl chloride.The acid is sulfuric acid and hydrochloric acid, and the base is aniline, piperidine 6503660 pyridine. Generally, acid is used as catalyst for the reaction of rutin with acid anhydride, and alkali is used as catalyst for the reaction of rutin with acyl chloride.
The feeding ratio is: rutin: anhydride or acyl chloride: acid or alkali = 1 mol: 1-10 ml: 0.05-1 ml.The feeding ratio is: rutin: anhydride or acyl chloride: acid or alkali = 1 mol: 1-10 ml: 0.05-1 ml.
The reaction temperature is controlled at 25-98°C, and stirring is carried out during the reaction. Heating can be done by electric heating jacket, microwave heating, water bath or oil bath.The reaction temperature is controlled at 25-98°C, and stirring is carried out during the reaction. Heating can be done by electric heating jacket, microwave heating, water bath or oil bath.
Rutin can be dissolved in a solvent before reaction, and the solvent is not particularly required, so long as rutin can be dissolved.Rutin can be dissolved in a solvent before reaction, and the solvent is not particularly required, so long as rutin can be dissolved.
Quercetin ester is generally prepared by the reaction of quercetin with anhydride or acyl chloride, and quercetin is prepared by the hydrolysis of rutin. In the invention, rutin reacts with anhydride or acyl chloride, and quercetin ester is directly prepared by one-pot boiling. In this method, rutin reacts with anhydride or acyl chloride under the action of acid or base (piperidine), and rutin tetraester is generated at first. At the same time of reaction, rutin glycosidic bond is broken under the action of by-product hydrogen chloride, and exposed quercetin 3- hydroxyl group further reacts with anhydride or acyl chloride to generate quercetin pentaester.Quercetin ester is generally prepared by the reaction of quercetin with anhydride or acyl chloride, and quercetin is prepared by the hydrolysis of rutin. In the invention, rutin reacts with anhydride or acyl chloride, and quercetin ester is directly prepared by one-pot boiling. In this method, rutin reacts with anhydride or acyl chloride under the action of acid or base (piperidine), and rutin tetraester is generated at first. At the same time of reaction, rutin glycosidic bond is broken under the action of by-product hydrogen chloride, and exposed quercetin 3- hydroxyl group further reacts with anhydride or acyl chloride to generate quercetin pentaester.
AH OCORAH OCOR
HOU A 50: (X ROCO 0 C 0 |. Dé (RCOHÔ or RCOC O | LeHOU A 50: (X ROCO 0 C 0 |. Dice (RCOHÔ or RCOC O | The
YY Nn gr Acid or base QCORYY Nn gr Acid or base QCOR
OH © ROCO ©OH © ROCO ©
The one-pot cooking method of the invention has the advantages of easily available reagents, mild conditions, few operation steps, labor and time saving, raw materials saving, emission reduction, less pollution and high yield, which lays a foundation for the effective utilization of quercetin derivatives, is a method with great popularization value, and conforms to the principle of sustainable development according to the principle of atomic economy.The one-pot cooking method of the invention has the advantages of easily available reagents, mild conditions, few operation steps, labor and time saving, raw materials saving, emission reduction, less pollution and high yield, which lays a foundation for the effective utilization of quercetin derivatives, is a method with great popularization value, and conforms to the principle of sustainable development according to the principle of atomic economy.
According to the different raw materials used, many different compounds can B&J503660 synthesized. The following 2-13 are new compounds that have never been reported before:According to the different raw materials used, many different compounds can B&J503660 synthesized. The following 2-13 are new compounds that have never been reported before:
ACOH; 27, SCOCHCHSACOH; 27, SCOCHCHS
OOOH. A 01 A HCHCOCHO, oO. AL AOOOH. AT 01 AT HCHCOCHO, oO. TO THE
Pood OY Y Sooo, TEN 1 7 ococHcH,Pood OY Y Sooo, TEN 1 7 ococHcH,
V4 ocook, YT ET OCOCHCH, 40000 0 HORCO00 ÙV4 ocook, YT AND OCOCHCH, 40000 0 HORCO00 Ù
Quercetin pentaacetate (3} M: 512 Quercetin pentapropionate (23 M:582 (FN ACCCgH A DOCH CHQuercetin pentaacetate (3} M: 512 Quercetin pentapropionate (23 M: 582 (FN ACCCgH A DOCH CH
CH DCHO 2 A. A I 0-H; CE OCHO. A a ) mi vf x x Fe GOOCH; AR N N ae” GLOC:HAH-0 oy Y SOCOGH Y Ÿ OCOC:H.CH20 i i ; ! 3CH DCHO 2 A. A I 0-H; THIS OCHO. A a ) mi vf x x Fe GOOCH; AR N N ae” GLOC:HAH-0 oy Y SOCOGH Y Ÿ OCOC:H.CH20 i i ; ! 3
CHO ö CC 9CHO ö CC 9
Quercetin pentabenzoate (3) M:822 Quercetin pentao-toiuic acid ester (43 M:892 25, OCOC HE Hz „A FOGGQuercetin pentabenzoate (3) M:822 Quercetin pentao-toiuic acid ester (43 M:892 25, OCOC HE Hz „A FOGG
CO OCHO = 0 A | HOCH OCHO. PA 0 ÀCO OCHO = 0 A | HOCH OCHO. PA 0 TO
A-HACC/HOCHD PR DE Peg ha wT NR Nee 1 w À À Nt Cr ys Y “OCOCHCHm j I QCOGHCHD i ; CPAS £ aHEO HO à pHCCHOC0 0A-HACC/HOCHD PR DE Peg ha wT NR Nee 1 w À À Nt Cr ys Y “OCOCHCHm j I QCOGHCHD i ; CPAS £ aHEO HO at pHCCHOC0 0
Quercetin pentam-metlw! benzoate (5) M802 Quercetin pentap-methyl berzoate (6) M:592Quercetin pentam-metlw! benzoate (5) M802 Quercetin pentap-methyl berzoate (6) M:592
LÉ ECOCHACH2}y5,5-4 AE ii oso A 0 2 0 PHCHOCHOCHO o_O A ÀLÉ ECOCHACH2}y5,5-4 AE ii oso A 0 2 0 PHCHOCHOCHO o_O A À
CGR AE 1 T u COOH SE C | y } SANCGR AE 1 T u COOH SE C | y } SAN
SO SE pySO SE py
NY O00CH C35 TY Teen wh d-5-3{Hk;Ch0H;000 à PHAHLGHOC0 DNY O00CH C35 TY Teen wh d-5-3{Hk;Ch0H;000 to PHAHLGHOC0 D
Quercetin penta (3, 5-dimethylbenzoie acid} ester {7} M:062 Quercetin pentaethy! benzoate (8) M862Quercetin penta (3, 5-dimethylbenzoie acid} ester {7} M:062 Quercetin pentaethy! benzoate (8) M862
The antitumor activities of the above compounds were tested, and all of them had good antitumor activities.The antitumor activities of the above compounds were tested, and all of them had good antitumor activities.
Compared with the prior art, the invention has the following advantages:Compared with the prior art, the invention has the following advantages:
The invention provides a plurality of new quercetin ester compounds which are synthesized by a one-pot method. The method has the advantages of easily available reagents, mild conditions, few operation steps, labor and time saving, raw material$J503660 saving, emission reduction, less pollution and high yield, which lays a foundation for the effective utilization of quercetin derivatives, is a method with great popularization value, and conforms to the principle of sustainable development according to the principle of atomic economy.The invention provides a plurality of new quercetin ester compounds which are synthesized by a one-pot method. The method has the advantages of easily available reagents, mild conditions, few operation steps, labor and time saving, raw material$J503660 saving, emission reduction, less pollution and high yield, which lays a foundation for the effective utilization of quercetin derivatives, is a method with great popularization value, and conforms to the principle of sustainable development according to the principle of atomic economy.
Fig. 1 shows a flow chart of conventional synthesis process of quercetin esterFig. 1 shows a flow chart of conventional synthesis process of quercetin ester
Fig. 2 shows a process flow chart of one-pot synthesis of quercetin esterFig. 2 shows a process flow chart of one-pot synthesis of quercetin ester
The following describes the technical scheme of the present invention with specific examples, but the protection scope of the present invention is not limited to this:The following describes the technical scheme of the present invention with specific examples, but the protection scope of the present invention is not limited to this:
In the following examples, the amount of acid or base catalyst is expressed in drops, and the volume of 20 drops is 1ml.In the following examples, the amount of acid or base catalyst is expressed in drops, and the volume of 20 drops is 1ml.
Example 1Example 1
Synthesis of quercetin pentaacetate (1)Synthesis of quercetin pentaacetate (1)
Weigh 610mg (1mmol) of rutin, add 5ml of acetic anhydride, stir for 0.5h with a magnetic stirrer, add 5 drops of concentrated sulfuric acid, control the temperature at 65°C, reflux for 6h, monitor the reaction progress with TLC plate, add 80mI of distilled water, stir for 2h, then after ultrasonic treatment at 300W for 50min, a large number of solids will precipitate until the solids precipitate and water become clear, discard the water layer, and wash the precipitate to neutrality. Adding 80mL of ethyl acetate to dissolve, passing through silica gel column, eluting with acetone: petroleum ether (3:2), collecting eluate, rotary steaming, and recrystallizing with chloroform/methanol, with a yield of 58.2%.Weigh 610mg (1mmol) of rutin, add 5ml of acetic anhydride, stir for 0.5h with a magnetic stirrer, add 5 drops of concentrated sulfuric acid, control the temperature at 65°C, reflux for 6h, monitor the reaction progress with TLC plate , add 80mI of distilled water, stir for 2h, then after ultrasonic treatment at 300W for 50min, a large number of solids will precipitate until the solids precipitate and water become clear, discard the water layer, and wash the precipitate to neutrality. Adding 80mL of ethyl acetate to dissolve, passing through silica gel column, eluting with acetone: petroleum ether (3:2), collecting eluate, rotary steaming, and recrystallizing with chloroform/methanol, with a yield of 58.2%.
Colorless crystal, m. p. 194.5-195.1°C (literature value: 195-196°C). IR (KBr),nv, em”: 2946.2, 1776.3, 1264.6, 1199.82. "HNMR (DMSO, 600MHz), à: 7.86 (m, 1H, 2-H); 7.84Colorless crystal, m. p. 194.5-195.1°C (literature value: 195-196°C). IR (KBr),nv, em”: 2946.2, 1776.3, 1264.6, 1199.82. "HNMR (DMSO, 600MHz), at: 7.86 (m, 1H, 2-H); 7.84
(m, 1H, 6'-H); 7.65 (s, 1H, 5'H); 7.55 (s, 1H, 8H); 6.17 (s, 1H, 6H); 2.34 (m, 15H, CHAU503660(m, 1H, 6'-H); 7.65 (s, 1H, 5'H); 7.55 (s, 1H, 8H); 6.17 (s, 1H, 6H); 2.34 (m, 15H, CHAU503660
MS, m/z: 513.1[M+1]*.MS, m/z: 513.1[M+1]*.
Example 2Example 2
Synthesis of quercetin pentapropionate (2)Synthesis of quercetin pentapropionate (2)
Weigh 610mg(1mmol) of rutin, add 5ml of propionic anhydride, stir it with a magnetic stirrer for 0.5h, then add 5 drops of concentrated sulfuric acid, control the temperature at 65°C, reflux for 6h, monitor the reaction progress with TLC plate, add 80mI of distilled water, stir for 2h, then after ultrasonic treatment at 300W for 50min, a large number of solids will precipitate until the solids precipitate and water become clear, and the precipitate will be washed to neutrality; adding 80mL of ethyl acetate to dissolve, passing through silica gel column, eluting with acetone: petroleum ether (3:2), collecting eluate, rotary steaming, and recrystallizing with chloroform/methanol. The yield is 57.3%. m. p.136.1-138.4 °C. IR (KBr), v, cm: 2936, 1769.2, 1244.6, 1108.8. "HNMR (CDCls, 600MHz), à: 7.86 (m, 1H, 2-H); 7.64 (m, 1H, 6-H); 7.60 (s, 1H, 5' H); 7.54 (s, 1H, 8H); 7.16 (s, 1H, 6H); 2.63-2.78 (d, 10H, CH); 1.16 (m, 15H, CHz). MS, m/z: 583.18[M+1]*.Weigh 610mg(1mmol) of rutin, add 5ml of propionic anhydride, stir it with a magnetic stirrer for 0.5h, then add 5 drops of concentrated sulfuric acid, control the temperature at 65°C, reflux for 6h, monitor the reaction progress with TLC plate, add 80mI of distilled water, stir for 2h, then after ultrasonic treatment at 300W for 50min, a large number of solids will precipitate until the solids precipitate and water become clear, and the precipitate will be washed to neutrality; adding 80mL of ethyl acetate to dissolve, passing through silica gel column, eluting with acetone: petroleum ether (3:2), collecting eluate, rotary steaming, and recrystallizing with chloroform/methanol. The yield is 57.3%. mr. p.136.1-138.4 °C. IR (KBr), v, cm: 2936, 1769.2, 1244.6, 1108.8. "HNMR (CDCls, 600MHz), at: 7.86 (m, 1H, 2-H); 7.64 (m, 1H, 6-H); 7.60 (s, 1H, 5' H); 7.54 (s, 1H, 8H ); 7.16 (s, 1H, 6H); 2.63-2.78 (d, 10H, CH); 1.16 (m, 15H, CHz). MS, m/z: 583.18[M+1]*.
Example 3Example 3
Synthesis of quercetin pentabenzoate (3)Synthesis of quercetin pentabenzoate (3)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of benzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 10 drops of piperidine, control the temperature at 65°C, reflux for 6h, monitor the reaction progress with TLC plate, add 80ml of distilled water, stir for 2h, and then ultrasonic at 300W for 50min, and a large number of solids will precipitate. The water layer was discarded until the solid was precipitated and the water became clear. The precipitate was washed with water until it was neutral, and 80mL of ethyl acetate was added to dissolve it. After passing through a silica gel column, acetone: petroleum ether (3:2) was eluted, and the eluent was collected for rotary evaporation. After recrystallization with chloroform/methanol, the yield was 57.3%, m. p. 112.3-1114.5°C. IR (KBr), v, cm”: 3406.0, 2926.1, 1745.3, 1259.6, 1129.8. "HNMR (CDCIs, 600MHz), à: 7.78 (m, 1H, 2'-H); 7.72 (m, 1H, 6'-H); 7.70 (s, 1H, 5'H); 7.66 (s, 1H, 6H); 6.17 (s, 1H, 8H); 7.62-8.04 (m, 25H, ph-H). MS, m/z: 823.18[M+1]*.Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of benzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 10 drops of piperidine, control the temperature at 65°C, reflux for 6h, monitor the reaction progress with TLC plate, add 80ml of distilled water, stir for 2h, and then ultrasonic at 300W for 50min, and a large number of solids will precipitate. The water layer was discarded until the solid was precipitated and the water became clear. The precipitate was washed with water until it was neutral, and 80mL of ethyl acetate was added to dissolve it. After passing through a silica gel column, acetone: petroleum ether (3:2) was eluted, and the eluent was collected for rotary evaporation. After recrystallization with chloroform/methanol, the yield was 57.3%, m. p. 112.3-1114.5°C. IR (KBr), v, cm”: 3406.0, 2926.1, 1745.3, 1259.6, 1129.8. "HNMR (CDCIs, 600MHz), at: 7.78 (m, 1H, 2'-H); 7.72 (m, 1H, 6'-H); 7.70 (s, 1H, 5'H); 7.66 (s, 1H , 6H); 6.17 (s, 1H, 8H); 7.62-8.04 (m, 25H, ph-H). MS, m/z: 823.18[M+1]*.
Example 4 LU503660Example 4 LU503660
Synthesis of quercetin pentao-toluic acid ester (4)Synthesis of quercetin pentao-toluic acid ester (4)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of o-methylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 6 drops of piperidine, control the temperature at 55°C, reflux it for Sh, monitor the reaction progress by TLC plate, add 80mI of distilled water, stir it for 2h, and then a large number of solids precipitate after ultrasonic treatment for 50min at 300W W. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water until it is neutral, then 80mL of methyl acetate is added to dissolve it, and it passes through a silica gel column, and acetone: petroleum ether (3:1) is eluted, and the eluent is collected for rotary evaporation and recrystallized by chloroform/methanol to obtain a white solid with a yield of 68.1%, m.p.118.6-119.8°C. IR (KBr), v, cm”: 3406.4, 2840.2, 1668.0, 1246.7, 1139.7. "HNMR (CDCIs, 600MHz), à: 8.20 (s, 1H, 2-H); 7.87 (m, 1H, 6-H); 7.76 (m, 1H, 5'H); 7.62 (s, 1H, 6H); 7.35 (m, 1H, 8H); 7.18-7.40 (m, 20H, ph-H); 2.20-2.84 (s, 15H, CHz). MS, m/z: 893.4[M+1]*.Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of o-methylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 6 drops of piperidine, control the temperature at 55°C , reflux it for Sh, monitor the reaction progress by TLC plate, add 80mI of distilled water, stir it for 2h, and then a large number of solids precipitate after ultrasonic treatment for 50min at 300W W. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water until it is neutral, then 80mL of methyl acetate is added to dissolve it, and it passes through a silica gel column, and acetone: petroleum ether (3:1 ) is eluted, and the eluent is collected for rotary evaporation and recrystallized by chloroform/methanol to obtain a white solid with a yield of 68.1%, m.p.118.6-119.8°C. IR (KBr), v, cm”: 3406.4, 2840.2, 1668.0, 1246.7, 1139.7. "HNMR (CDCIs, 600MHz), at: 8.20 (s, 1H, 2-H); 7.87 (m, 1H, 6-H); 7.76 (m, 1H, 5'H); 7.62 (s, 1H, 6H ); 7.35 (m, 1H, 8H); 7.18-7.40 (m, 20H, ph-H); 2.20-2.84 (s, 15H, CHz). MS, m/z: 893.4[M+1]*.
Example 5Example 5
Synthesis of quercetin pentam-methyl benzoate (5)Synthesis of quercetin pentam-methyl benzoate (5)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of m-methylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 8 drops of piperidine, control the temperature at 60°C, reflux for 6h, monitor the reaction progress with TLC plate, add 80mI of distilled water, stir for 2h, and then a large number of solids precipitate after ultrasonic treatment for 50min at 300W W. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water until it is neutral. Then, 80mL of n-propyl acetate is added to dissolve it, and it is eluted by silica gel column and acetone: petroleum ether (2:2), and the eluent is collected for rotary evaporation, and then it is recrystallized by chloroform/methanol to obtain a white solid with a yield of 54.4%, m. p. 121.1-123.6°C. IR (KBr), v, cm”: 3414.8, 2907.3, 1775.4, 1286.8, 1068.7. "HNMR (CDCIs, 600MHz), 8.27 (s, 1H, 2-H, ph-H); 8.17 (m, 1H, 6-H, ph-H); 8.03 (s, 1H, 5'H); 7.61 (s, 1H, 6H); 7.45 (s, 1H, 8H); 7.36-7.79 (m, 20H, ph-H); 2.07-2.83 (s, 15H, CHz). MS, m/z: 893.3[M+1]*.Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of m-methylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 8 drops of piperidine, control the temperature at 60°C , reflux for 6h, monitor the reaction progress with TLC plate, add 80mI of distilled water, stir for 2h, and then a large number of solids precipitate after ultrasonic treatment for 50min at 300W W. When the solid is precipitated and the water becomes clear , the water layer is discarded, and the precipitate is washed with water until it is neutral. Then, 80mL of n-propyl acetate is added to dissolve it, and it is eluted by silica gel column and acetone: petroleum ether (2:2), and the eluent is collected for rotary evaporation, and then it is recrystallized by chloroform/ methanol to obtain a white solid with a yield of 54.4%, m. p. 121.1-123.6°C. IR (KBr), v, cm”: 3414.8, 2907.3, 1775.4, 1286.8, 1068.7. "HNMR (CDCIs, 600MHz), 8.27 (s, 1H, 2-H, ph-H); 8.17 (m, 1H, 6-H, ph-H); 8.03 (s, 1H, 5'H); 7.61 (s, 1H, 6H); 7.45 (s, 1H, 8H); 7.36-7.79 (m, 20H, ph-H); 2.07-2.83 (s, 15H, CHz). MS, m/z: 893.3[M +1]*.
Example 6 LU503660Example 6 LU503660
Synthesis of quercetin penta-p-methyl benzoate (6)Synthesis of quercetin penta-p-methyl benzoate (6)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of p-toluoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 7 drops of piperidine, control the temperature at 50°C, reflux it for 5h, monitor the reaction progress with TLC plate, add 80ml of distilled water, stir it for 2h, and then a large number of solids precipitate after ultrasonic treatment for 50min at 300W W. When the solid is precipitated and the water becomes clear, the water layer is discarded, the precipitate is washed with water to neutrality, 70mL of methyl acetate is added for dissolution, and then eluted by silica gel column and acetone: petroleum ether (3:2.5), and the eluent is collected for rotary evaporation, and then recrystallized by chloroform/methanol to obtain a white solid with a yield of 43.8%, m. p. 126.3-127.5°C. IR(KBr), v, cm": 3308.2, 2897.3, 1738.9, 1328.4, 1029.6. "HNMR (CDCIs, 600MHz), à: 7.86 (m, 1H, 2-H); 7.65 (m, 1H, 6-H); 7.55 (s, 1H, 5'H); 7.52 (s, 1H, 6H); 7.17 (s, 1H, 8H); 7.14-7.83 (m, 20H, ph-H); 2.39-2.65 (s, 15H, CHz). MS, m/z: 893.3[M+1]*.Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of p-toluoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 7 drops of piperidine, control the temperature at 50°C , reflux it for 5h, monitor the reaction progress with TLC plate, add 80ml of distilled water, stir it for 2h, and then a large number of solids precipitate after ultrasonic treatment for 50min at 300W W. When the solid is precipitated and the water becomes clear, the water layer is discarded, the precipitate is washed with water to neutrality, 70mL of methyl acetate is added for dissolution, and then eluted by silica gel column and acetone: petroleum ether (3:2.5), and the eluent is collected for rotary evaporation, and then recrystallized by chloroform/methanol to obtain a white solid with a yield of 43.8%, m. p. 126.3-127.5°C. IR(KBr), v, cm": 3308.2, 2897.3, 1738.9, 1328.4, 1029.6. "HNMR (CDCIs, 600MHz), at: 7.86 (m, 1H, 2-H); 7.65 (m, 1H, 6-H); 7.55 (s, 1H, 5'H); 7.52 (s, 1H, 6H); 7.17 (s, 1H, 8H); 7.14-7.83 (m, 20H, ph-H); 2.39-2.65 (s, 15H, CHz). MS, m/z: 893.3[M+1]*.
Example 7Example 7
Synthesis of quercetin penta (3,5- dimethyl) benzoate (7)Synthesis of quercetin penta (3,5-dimethyl) benzoate (7)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add ml of 3,5-dimethylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 10 drops of piperidine, control the temperature at 58°C, reflux for 4h, monitor the reaction progress by TLC plate to ensure the complete reaction, add 80ml of distilled water, stir for 2h, Then, after ultrasonic treatment for 50min at a power of 300W, a large number of solids were precipitated until the solids were precipitated and the water became clear and the water layer was discarded. The precipitate was washed with water until it was neutral, and 65mL of methyl acetate was added to dissolve it. After passing through a silica gel column, ethyl acetate: dichloromethane (3:2) was eluted, and the eluent was collected for rotary evaporation. After recrystallization by chloroform/methanol, a white solid was obtained with a yield of 61.1%, m. p. 132.6-133.1°C. IR(KBr), v, cm: 3518.2, 2802.6, 1721.8, 1259.7, 1129.6. "HNMR (CDCl, 600MHz), à: 7.91 (s, 1H, 2'-H); 7.78 (m,Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add ml of 3,5-dimethylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 10 drops of piperidine, control the temperature at 58 °C, reflux for 4h, monitor the reaction progress by TLC plate to ensure the complete reaction, add 80ml of distilled water, stir for 2h, Then, after ultrasonic treatment for 50min at a power of 300W, a large number of solids were precipitated until the solids were precipitated and the water became clear and the water layer was discarded. The precipitate was washed with water until it was neutral, and 65mL of methyl acetate was added to dissolve it. After passing through a silica gel column, ethyl acetate: dichloromethane (3:2) was eluted, and the eluent was collected for rotary evaporation. After recrystallization by chloroform/methanol, a white solid was obtained with a yield of 61.1%, m. p. 132.6-133.1°C. IR(KBr), v, cm: 3518.2, 2802.6, 1721.8, 1259.7, 1129.6. "HNMR (CDCl, 600MHz), at: 7.91 (s, 1H, 2'-H); 7.78 (m,
1H, 6'-H); 7.58 (s, 1H, 5'H); 7.43 (s, 1H, 6H); 7.26 (s, 1H, 8H); 7.25-7.67 (m, 15H, ph-H)U503660 2.17-2.35 (s, 30H, CHz). MS, m/z: 963.5[M+1]*.1H, 6'-H); 7.58 (s, 1H, 5'H); 7.43 (s, 1H, 6H); 7.26 (s, 1H, 8H); 7.25-7.67 (m, 15H, ph-H)U503660 2.17-2.35 (s, 30H, CHz). MS, m/z: 963.5[M+1]*.
Example 8Example 8
Synthesis of quercetin pentaethyl benzoate (8)Synthesis of quercetin pentaethyl benzoate (8)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of p-ethylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 12 drops of piperidine, control the temperature at 62°C, reflux for 4h, monitor the reaction progress by TLC plate to ensure the complete reaction, add 80mI of distilled water, stir for 2h,Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of p-ethylbenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 12 drops of piperidine, control the temperature at 62°C , reflux for 4h, monitor the reaction progress by TLC plate to ensure the complete reaction, add 80mI of distilled water, stir for 2h,
Then, after ultrasonic treatment for 50min at a power of 300W, a large number of solids were precipitated until the solids were precipitated and the water became clear and the water layer was discarded. The precipitate was washed with water until it was neutral, and 82mL of ethyl acetate was added for dissolution. After passing through a silica gel column, ethyl acetate: dichloromethane (3:1) was eluted, and the eluent was collected for rotary evaporation. After recrystallization by chloroform/methanol, a white solid was obtained with a yield of 63.4%, m. p. 130.1-131.6°C. IR(KBr), v, cm": 3416.3, 2901.2, 1725.3, 1248.8, 1069.8. "HNMR (CDCIs, 600MHz), à: 7.79 (m, 1H, 2-H); 7.76 (m, 1H, 6-H); 7.74 (s, 1H, 5'H); 7.66 (s, 1H, 6H); 6.17 (s, 1H, 8H); 7.25-7.67 (m, 20H, ph-H); 2.27-2.52 (s, 15H, CHz); 0.97-1.08 (m, 10H, CH). MS, m/z: 963.2[M+1]*.Then, after ultrasonic treatment for 50min at a power of 300W, a large number of solids were precipitated until the solids were precipitated and the water became clear and the water layer was discarded. The precipitate was washed with water until it was neutral, and 82mL of ethyl acetate was added for dissolution. After passing through a silica gel column, ethyl acetate: dichloromethane (3:1) was eluted, and the eluent was collected for rotary evaporation. After recrystallization by chloroform/methanol, a white solid was obtained with a yield of 63.4%, m. p. 130.1-131.6°C. IR(KBr), v, cm": 3416.3, 2901.2, 1725.3, 1248.8, 1069.8. "HNMR (CDCIs, 600MHz), at: 7.79 (m, 1H, 2-H); 7.76 (m, 1H, 6-H); 7.74 (s, 1H, 5'H); 7.66 (s, 1H, 6H); 6.17 (s, 1H, 8H); 7.25-7.67 (m, 20H, ph-H); 2.27-2.52 (s, 15H, CHz); 0.97-1.08 (m, 10H, CH). MS, m/z: 963.2[M+1]*.
Example 9Example 9
Synthesis of quercetin pentaphenylacetate (9)Synthesis of quercetin pentaphenylacetate (9)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of phenylacetyl chloride, stir it with a magnetic stirrer for 0.5h, then add 9 drops of piperidine, control the temperature at 57°C, reflux for 4h, monitor the reaction progress by TLC plate, add 80ml of distilled water, stir for 2h, and then ultrasonic at 300W for 50min, and a large number of solids will precipitate. Discard the water layer until the solid is precipitated and the water becomes clear, wash the precipitate with water until it is neutral, add 68mL of methyl acetate to dissolve it, pass through a silica gel column, elute with ethyl acetate and dichloromethane (2:3), collect the eluent, and evaporate it by rotary evaporation, and recrystallize it with chloroform/methanol to obtain a white solid with a yield of 60.5%, m. p. 129.5-130.2°C. IR(KBr), v, cm”: 3446.8, 2922.8, 1725.3,Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of phenylacetyl chloride, stir it with a magnetic stirrer for 0.5h, then add 9 drops of piperidine, control the temperature at 57°C, reflux for 4h, monitor the reaction progress by TLC plate, add 80ml of distilled water, stir for 2h, and then ultrasonic at 300W for 50min, and a large number of solids will precipitate. Discard the water layer until the solid is precipitated and the water becomes clear, wash the precipitate with water until it is neutral, add 68mL of methyl acetate to dissolve it, pass through a silica gel column, elute with ethyl acetate and dichloromethane (2: 3), collect the eluent, and evaporate it by rotary evaporation, and recrystallize it with chloroform/methanol to obtain a white solid with a yield of 60.5%, m. p. 129.5-130.2°C. IR(KBr), v, cm”: 3446.8, 2922.8, 1725.3,
1237.4, 1057.6. 'HNMR (CDCIs, 600MHz), à: 7.78 (m, 1H, 2'-H); 7.75 (m, 1H, 6'-H); 7.74J503660 (s, 1H, 5'H); 7.61 (s, 1H, 6H); 6.19 (s, 1H, 8H); 7.26-7.69 (m, 25H, ph-H); 0.98-1.09 (m, 10H, CHz). MS, m/z: 893.4[M+1]*.1237.4, 1057.6. 'HNMR (CDCIs, 600MHz), at: 7.78 (m, 1H, 2'-H); 7.75 (m, 1H, 6'-H); 7.74J503660 (s, 1H, 5'H); 7.61 (s, 1H, 6H); 6.19 (s, 1H, 8H); 7.26-7.69 (m, 25H, ph-H); 0.98-1.09 (m, 10H, CHz). MS, m/z: 893.4[M+1]*.
Example 10Example 10
Synthesis of quercetin pentao-chlorobenzoic acid ester (10)Synthesis of quercetin pentao-chlorobenzoic acid ester (10)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of o-chlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 12 drops of piperidine, control the temperature at 75°C, reflux for 4h, and monitor the reaction progress by TLC plate to ensure the complete reaction. Adding 80ml distilled water, stirring for 2 hours, and then ultrasonic for 50min minutes at a power of 300W, a large number of solids were precipitated. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water until it is neutral, and 68mL of ethyl acetate is added to dissolve it, then it passes through a silica gel column, methyl acetate: dichloromethane (3:2) is eluted, and the eluent is collected for rotary evaporation, and then it is recrystallized by chloroform/methanol to obtain a white solid with a yield of 58.8%, m. p. 132.6-133.1°C. IR(KBr), v, cm: 3408.7, 1663.1, 1168.9, 1014.7. "HNMR (CDCIs, 600MHz), à: 8.25 (m, 1H, 2'-H); 8.15 (m, 1H, 6'-H); 8.08 (s, 1H, 5'H); 8.01 (s, 1H, 6H); 7.50 (s, 1H, 8H); 7.01-7.90 (m, 20H, ph-H). MS, m/z: 995.1[M+1]*.Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of o-chlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 12 drops of piperidine, control the temperature at 75°C , reflux for 4h, and monitor the reaction progress by TLC plate to ensure the complete reaction. Adding 80ml distilled water, stirring for 2 hours, and then ultrasonic for 50min minutes at a power of 300W, a large number of solids were precipitated. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water until it is neutral, and 68mL of ethyl acetate is added to dissolve it, then it passes through a silica gel column, methyl acetate: dichloromethane (3:2) is eluted, and the eluent is collected for rotary evaporation, and then it is recrystallized by chloroform/methanol to obtain a white solid with a yield of 58.8%, m. p. 132.6-133.1°C. IR(KBr), v, cm: 3408.7, 1663.1, 1168.9, 1014.7. "HNMR (CDCIs, 600MHz), at: 8.25 (m, 1H, 2'-H); 8.15 (m, 1H, 6'-H); 8.08 (s, 1H, 5'H); 8.01 (s, 1H , 6H); 7.50 (s, 1H, 8H); 7.01-7.90 (m, 20H, ph-H). MS, m/z: 995.1[M+1]*.
Example 11Example 11
Synthesis of Quercetin Pentachlorobenzoate (11)Synthesis of Quercetin Pentachlorobenzoate (11)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of p-chlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 11 drops of piperidine, control the temperature at 74°C, reflux for 4h, monitor the reaction progress with TLC plate to ensure that the reaction is complete, add 80mI of distilled water, stir for 2h, and after ultrasonic treatment for 50min at 300W, a large amount of solids will be produced. Discard the water layer until the solid is precipitated and the water becomes clear, wash the precipitate with water until it is neutral, add 78mL of ethyl acetate to dissolve it, pass through a silica gel column, elute with methyl acetate: dichloromethane (3:1), collect the eluent, and evaporate it by rotary evaporation, and recrystallize it with chloroform/methanol to obtain a white solid with a yield of 61.3%, m. p. 132.6-134.1°CU503660Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5ml of p-chlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 11 drops of piperidine, control the temperature at 74°C , reflux for 4h, monitor the reaction progress with TLC plate to ensure that the reaction is complete, add 80mI of distilled water, stir for 2h, and after ultrasonic treatment for 50min at 300W, a large amount of solids will be produced. Discard the water layer until the solid is precipitated and the water becomes clear, wash the precipitate with water until it is neutral, add 78mL of ethyl acetate to dissolve it, pass through a silica gel column, elute with methyl acetate: dichloromethane (3: 1), collect the eluent, and evaporate it by rotary evaporation, and recrystallize it with chloroform/methanol to obtain a white solid with a yield of 61.3%, m. p. 132.6-134.1°CU503660
IR(KBr), v, cm‘: 3436.2, 1785.2, 1247.9, 1019.4. "HNMR (CDCIs, 600MHz), & 8.19 (m, 1H, 2-H); 7.84 (s, 1H, 6-H); 7.52 (m, 1H, 5H); 7.47 (s, 1H, 6H); 7.25 (s, 1H, 8H); 7.18-7.90 (m, 20H, ph-H). MS, m/z: 955.2[M+1]*.IR(KBr), v, cm‘: 3436.2, 1785.2, 1247.9, 1019.4. "HNMR (CDCIs, 600MHz), & 8.19 (m, 1H, 2-H); 7.84 (s, 1H, 6-H); 7.52 (m, 1H, 5H); 7.47 (s, 1H, 6H); 7.25 (s, 1H, 8H); 7.18-7.90 (m, 20H, ph-H). MS, m/z: 955.2[M+1]*.
Example 12Example 12
Synthesis of quercetin penta (2,3-dichlorobenzoic acid) ester (12)Synthesis of quercetin penta (2,3-dichlorobenzoic acid) ester (12)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add ml of 2,3-dichlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 15 drops of piperidine, control the temperature at 78°C, reflux for 4h, and monitor the reaction progress by TLC plate to ensure the complete reaction. Adding 80ml distilled water, stirring for 2 hours, and then ultrasonic for 50min minutes at a power of 300W, a large number of solids were precipitated. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water to be neutral, then 70mL of ethyl acetate is added to dissolve it, and it passes through a silica gel column, and methyl acetate: dichloromethane (2:3) is eluted, and the eluent is collected for rotary evaporation and recrystallized by chloroform/methanol to obtain a white solid with a yield of 52.4%, m. p. 137.6°C. IR(KBr), v, cm”: 3466.1, 1794.2, 1347.6, 1121.6. "HNMR (CDCIs, 600MHz), à: 8.33 (m, 1H, 2-H); 8.17 (m, 1H, 6-H); 7.83 (s, 1H, 5H); 7.55 (s, 1H, 6H), 7.20 (s, 1H, 8H), 7.30-7.93 (m, 15H, ph-H). MS, m/z: 1169.0[M+1]*.Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add ml of 2,3-dichlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 15 drops of piperidine, control the temperature at 78 °C, reflux for 4h, and monitor the reaction progress by TLC plate to ensure the complete reaction. Adding 80ml distilled water, stirring for 2 hours, and then ultrasonic for 50min minutes at a power of 300W, a large number of solids were precipitated. When the solid is precipitated and the water becomes clear, the water layer is discarded, and the precipitate is washed with water to be neutral, then 70mL of ethyl acetate is added to dissolve it, and it passes through a silica gel column, and methyl acetate: dichloromethane (2:3) is eluted, and the eluent is collected for rotary evaporation and recrystallized by chloroform/methanol to obtain a white solid with a yield of 52.4%, m. p. 137.6°C. IR(KBr), v, cm”: 3466.1, 1794.2, 1347.6, 1121.6. "HNMR (CDCIs, 600MHz), at: 8.33 (m, 1H, 2-H); 8.17 (m, 1H, 6-H); 7.83 (s, 1H, 5H); 7.55 (s, 1H, 6H), 7.20 (s, 1H, 8H), 7.30-7.93 (m, 15H, ph-H). MS, m/z: 1169.0[M+1]*.
Example 13Example 13
Synthesis of quercetin penta (3,4-dichlorobenzoic acid) ester (13)Synthesis of quercetin penta (3,4-dichlorobenzoic acid) ester (13)
Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5 ml of 3,4-dichlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 14 drops of piperidine, control the temperature at 77°C, reflux for 4h, and monitor the reaction progress by TLC plate to ensure the complete reaction. Adding 80ml distilled water, stirring for 2 hours, and then ultrasonic for 50min minutes at a power of 300W, a large number of solids were precipitated. Discard the water layer until the solid is precipitated and the water becomes clear, wash the precipitate with water until it is neutral, add 70mL of ethyl acetate to dissolve it, pass through a silica gel column, elute with methyl acetate: dichloromethane (3:1.5), collect the eluate, and evaporate it kyJ503660 rotary evaporation, and recrystallize it with chloroform/methanol to obtain a white solid with a yield of 51.6%, m. p. 132.6-133.1°C. IR(KBr), v, cm”: 3370.2, 1791.7, 1233.9, 1011.3. 'THNMR (CDCIs, 600MHz), à: 7.79 (m, 1H, 2'-H); 7.76 (m, 1H, 6-H); 7.74 (s, 1H, 5'H); 7.66 (s, 1H, 6H); 6.17 (s, 1H, 8H); 7.25-7.67 (m, 15H, ph-H). MS, m/z: 1166.9[M+1]Weigh 610mg(1mmol) of rutin, dissolve it in 20ml of dimethylformamide (DMF), add 5 ml of 3,4-dichlorobenzoyl chloride, stir it with a magnetic stirrer for 0.5h, then add 14 drops of piperidine, control the temperature at 77°C, reflux for 4h, and monitor the reaction progress by TLC plate to ensure the complete reaction. Adding 80ml distilled water, stirring for 2 hours, and then ultrasonic for 50min minutes at a power of 300W, a large number of solids were precipitated. Discard the water layer until the solid is precipitated and the water becomes clear, wash the precipitate with water until it is neutral, add 70mL of ethyl acetate to dissolve it, pass through a silica gel column, elute with methyl acetate: dichloromethane (3: 1.5), collect the eluate, and evaporate it kyJ503660 rotary evaporation, and recrystallize it with chloroform/methanol to obtain a white solid with a yield of 51.6%, m. p. 132.6-133.1°C. IR(KBr), v, cm”: 3370.2, 1791.7, 1233.9, 1011.3. 'THNMR (CDCIs, 600MHz), at: 7.79 (m, 1H, 2'-H); 7.76 (m, 1H, 6-H); 7.74 (s, 1H, 5'H); 7.66 (s, 1H, 6H); 6.17 (s, 1H, 8H); 7.25-7.67 (m, 15H, ph-H). MS, m/z: 1166.9[M+1]
Anti-tumor activity experimentAnti-tumor activity experiment
MTT assay was used to detect the inhibitory effects of quercetin and its esters at different concentrations on the proliferation of EC109 cells, EC9706 cells, B16-F10 cells and SGC-7901 cells. Logarithmic growth cells were collected, and the concentration was adjusted to 6x10° cells/well, and inoculated into 96-well culture plates, with 200uL per well. 5% CO», saturated humidity and 37°C incubator. When the cells adhered to the wall, the final concentration of quercetin diluted with RPMI1640 medium was 0.5, 1, 2, 4, 8, 16, 32, 64 and 128 pg/mL in the experimental group, and the complete medium was added in the solvent control group, with the final volume of each well being 200 uL, and each group was provided with 6 multiple wells. After 72 h of culture, the culture plate was taken out, and the morphology was observed under the inverted microscope and photographed. Then add 5 mg/mL MTT (20 uL/ well) to continue the culture for 4 h, pour out the original culture solution, then wash each well with PBS, add DMSO (150 uL/ well), shake well to dissolve the precipitate, and after 20 min at room temperature (magenta solution), detect the light absorption value (A value) of each well at 570 nm on an enzyme-linked immunosorbent assay. The experiment was repeated independently for 3 times, and the average value was taken, and the growth inhibition rate was calculated according to formula (1). According to the obtained results, the /Cso value is calculated by using SPPS19.0.MTT assay was used to detect the inhibitory effects of quercetin and its esters at different concentrations on the proliferation of EC109 cells, EC9706 cells, B16-F10 cells and SGC-7901 cells. Logarithmic growth cells were collected, and the concentration was adjusted to 6x10° cells/well, and inoculated into 96-well culture plates, with 200uL per well. 5% CO”, saturated humidity and 37°C incubator. When the cells adhered to the wall, the final concentration of quercetin diluted with RPMI1640 medium was 0.5, 1, 2, 4, 8, 16, 32, 64 and 128 pg/mL in the experimental group, and the complete medium was added in the solvent control group, with the final volume of each well being 200 uL, and each group was provided with 6 multiple wells. After 72 h of culture, the culture plate was taken out, and the morphology was observed under the inverted microscope and photographed. Then add 5 mg/mL MTT (20 uL/ well) to continue the culture for 4 h, pour out the original culture solution, then wash each well with PBS, add DMSO (150 uL/ well), shake well to dissolve the precipitate , and after 20 min at room temperature (magenta solution), detect the light absorption value (A value) of each well at 570 nm on an enzyme-linked immunosorbent assay. The experiment was repeated independently for 3 times, and the average value was taken, and the growth inhibition rate was calculated according to formula (1). According to the obtained results, the /Cso value is calculated by using SPPS19.0.
Gl! (growth inhibition rate) = 1- (A value of drug group/A value of control group) x100%, the antitumor activities of 13 quercetin esters and quercetin were preliminarily evaluated by MTT assay. Taking fluorouracil as the positive control, the inhibitory effects of the target compound on human esophageal squamous cell carcinoma (EC109),Gl! (growth inhibition rate) = 1- (A value of drug group/A value of control group) x100%, the antitumor activities of 13 quercetin esters and quercetin were preliminarily evaluated by MTT assay. Taking fluorouracil as the positive control, the inhibitory effects of the target compound on human esophageal squamous cell carcinoma (EC109),
human esophageal squamous cell carcinoma (EC9706), human gastric cancer célU503660 (SGC7901) and mouse melanoma cell (B16-F10) were investigated respectively.human esophageal squamous cell carcinoma (EC9706), human gastric cancer celU503660 (SGC7901) and mouse melanoma cell (B16-F10) were investigated respectively.
As can be seen from Table 1, quercetin has relatively good inhibitory effects onAs can be seen from Table 1, quercetin has relatively good inhibitory effects on
EC109 and EC9706 cells, while the /Cso values of the other two cells are both greater than 128 pmol/L. Thirteen kinds of quercetin ester derivatives synthesized have different degrees of inhibitory effects on these four cancer cells, and quercetin pentachlorophenate has good inhibitory effects on human esophageal squamous cell carcinoma (EC109) and human esophageal squamous cell carcinoma (EC9706).EC109 and EC9706 cells, while the /Cso values of the other two cells are both greater than 128 pmol/L. Thirteen kinds of quercetin ester derivatives synthesized have different degrees of inhibitory effects on these four cancer cells, and quercetin pentachlorophenate has good inhibitory effects on human esophageal squamous cell carcinoma (EC109) and human esophageal squamous cell carcinoma (EC9706).
Table 1 Proliferation inhibition rate of quercetin ester on different tumor cells (SD)Table 1 Proliferation inhibition rate of quercetin ester on different tumor cells (SD)
/Cso/ (umol-L"*)/Cso/ (umol-L"*)
EC109 EC9706EC109 EC9706
Serial Human Human SGC7901Serial Human Human SGC7901
Compound B16-F10 numb esophageal esophageal Human a Mouse er squamous squamous gastric melanoma cell cell cancer carcinoma carcinoma 29.182+1.41 193.444+1.62 115.18+1.83 1 CHz- 68.845+1.175 7 8 0 64.142+1.57 271.835+2.1 2 CH3CHz- 56.23+1.931 61.957+1.635 3 44 55.361+1.28 113.284+1.68 186.352+1.62 153.294+1.3 3 OO 4 2 7 46Compound B16-F10 numb esophageal esophageal Human a Mouse er squamous squamous gastric melanoma cell cell cancer carcinoma carcinoma 29.182+1.41 193.444+1.62 115.18+1.83 1 CHz- 68.845+1.175 7 8 0 64.142+1.57 271.835 +2.1 2 CH3CHz- 56.23+1.931 61.957+1.635 3 44 55.361+1.28 113.284+1.68 186.352+1.62 153.294+1.3 3 OO 4 2 7 46
H 86.356+1.75 108.397+1.62 189.391+1.53 98.267+1.38 4 as 8 1 1 0 128.367+1.2 162.591+1.65 138.362+1.2 84.576+1.197H 86.356+1.75 108.397+1.62 189.391+1.53 98.267+1.38 4 aces 8 1 1 0 128.367+1.2 162.591+1.65 138.362+1.2 84.576+1.197
H 13 9 56H 13 9 56
H + — 46.274+1.39 129.312+1.69 110.613+1.24 83.612+1.29 6 7 0 7 1H + — 46.274+1.39 129.312+1.69 110.613+1.24 83.612+1.29 6 7 0 7 1
HsH 59.618+1.25 114.326+1.27 127.291+1.5 7 91.503+1.153HsH 59.618+1.25 114.326+1.27 127.291+1.5 7 91.503+1.153
HoH 0 1 70 101.153+1.1 218.187+2.1 8 : A) 51.62+1.168 61.523+1.231 26 16 57.086+1.17 63.897+1.138 125.314+1.13 82.542+1.26 0H 3 4 7 77.820+1.05 46.287+1.348 81.169+1.192 69.324+1.12HoH 0 1 70 101.153+1.1 218.187+2.1 8: A) 51.62+1.168 61.523+1.231 26 16 57.086+1.17 63.897+1.138 125.314+1.13 82.542+1.26 0H 3 4 7 77.820+1.05 46.287+1.348 81.169+1.192 69.324+1.12
Oo - 11 —~ 28.446+1.62 26.562+1.267 87.691+1.651 79.318+1.57Oo - 11 —~ 28.446+1.62 26.562+1.267 87.691+1.651 79.318+1.57
2 LU503660 a 47.041+1.74 127.264+1.19 102.328+1.1 12 a 96.167+1.138 0 4 62 81.259+1.26 121.328+1.18 92.165+1.51 13 | ) 3 82.271+1.160 8 6 6 31.924+0.68 125.183+1.24 191.357+1.73 14 Quercetin - 4 4 5 41.738+0.73 182.115+1.3 5-FU 78.431+1.008 62.562+0.910 4 742 LU503660 a 47.041+1.74 127.264+1.19 102.328+1.1 12 a 96.167+1.138 0 4 62 81.259+1.26 121.328+1.18 92.165+1.51 13 | ) 3 82.271+1.160 8 6 6 31.924+0.68 125.183+1.24 191.357+1.73 14 Quercetin - 4 4 5 41.738+0.73 182.115+1.3 5-FU 78.431+1.008 62.56 2+0.910 4 74
The /Cso values of quercetin pentachlorobenzoate on human esophageal squamous cell carcinoma (EC109) reached 28.446 pmol/L, which was far less than that of quercetin (31.924 pmol/L) and better than that of 5-FU (41.738 umol/L), and it is expected to be a candidate drug for esophageal squamous cell carcinoma. In addition, other compounds showed certain inhibitory effects on four kinds of cancer cells.The /Cso values of quercetin pentachlorobenzoate on human esophageal squamous cell carcinoma (EC109) reached 28.446 pmol/L, which was far less than that of quercetin (31.924 pmol/L) and better than that of 5-FU (41.738 umol/L) , and it is expected to be a candidate drug for esophageal squamous cell carcinoma. In addition, other compounds showed certain inhibitory effects on four kinds of cancer cells.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU503660A LU503660B1 (en) | 2023-03-15 | 2023-03-15 | METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS AND APPLICATION THEREOF |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU503660A LU503660B1 (en) | 2023-03-15 | 2023-03-15 | METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS AND APPLICATION THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
LU503660B1 true LU503660B1 (en) | 2023-09-15 |
Family
ID=88068155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU503660A LU503660B1 (en) | 2023-03-15 | 2023-03-15 | METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS AND APPLICATION THEREOF |
Country Status (1)
Country | Link |
---|---|
LU (1) | LU503660B1 (en) |
-
2023
- 2023-03-15 LU LU503660A patent/LU503660B1/en active IP Right Grant
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1721903A1 (en) | Compositions and therapeutic methods involving isoflavones and analogues thereof | |
Shimada et al. | Chloroisosulochrin, chloroisosulochrin dehydrate, and pestheic acid, plant growth regulators, produced by Pestalotiopsis theae | |
Zhang et al. | First synthesis and biological evaluation of novel spin-labeled derivatives of deoxypodophyllotoxin | |
Maria Zbancioc et al. | Synthesis and in vitro analysis of novel dihydroxyacetophenone derivatives with antimicrobial and antitumor activities | |
Shinya et al. | Benthocyanins B and C, new free radical scavengers from Streptomyces prunicolor | |
CN110028546B (en) | Cyclopentane-polyhydrophenanthrene framework compound with function of regulating blood coagulation factor VIII level to play anti-tumor role and application thereof | |
LU503660B1 (en) | METHOD FOR SYNTHESIZING QUERCETIN ESTER BY ONE-POT, PRODUCTS AND APPLICATION THEREOF | |
CN106946972A (en) | A kind of ursolic acid derivative with antitumor activity and preparation method thereof | |
CN101402573A (en) | Bihydroxyl-2-acyl benzene acetic acid ester, producing method and uses thereof | |
JP2012528801A (en) | Method for synthesizing glycyrrhetinic ester derivative and deoxyglycyrrhetinic ester compound | |
CN109096357B (en) | Synthesis and application of naphthalene imide derivative containing thioether and cholesterol ester | |
Benedeković et al. | Design, synthesis and cytotoxic activity of new 6-O-aroyl (−)-cleistenolide derivatives | |
CN107698648B (en) | Naphthylimide derivative containing cholesterol and synthesis and application thereof | |
CN109485688B (en) | Triterpene derivative, and pharmaceutical composition and application thereof | |
AU2016214849B2 (en) | Compound, and separation method, synthesis method and use thereof | |
US4061773A (en) | Glycyrrhetinic acid derivatives | |
CN109320488B (en) | Water phase one-pot synthesis method of 3-hydroxyflavone and derivatives thereof | |
CN110143927B (en) | Benzimidazole chalcone derivative and preparation method and application thereof | |
CN109678832A (en) | One pot synthesis is synthesized the method and its product and application of Quercetin ester by rutin | |
Anastasiou et al. | On the formation of homo‐azasteroidal esters of N, N‐bis (2‐chloroethyl) aminobenzoic acid isomers and their antitumor activity | |
CN1850828A (en) | Podophyllotoxin derivatives and their preparing method | |
Jin et al. | Esters of chlorambucil with 2-substituted 1, 4-dihydroxy-9, 10-anthraquinones as multifunctional anticancer agents | |
FI62531B (en) | PROCEDURE FOR THERAPEUTIC ADMINISTRATION OF THERAPEUTIC 3-YAN-N- (N N-DIMETHYLAMINO-PROPYL) -IMINOBENSYL OCH SYRAADDIT IOSSALTER DAERAV | |
CN115785189B (en) | 5 alpha, 8 alpha-peroxosterol-17-phenylthiazole derivative and synthetic method and application thereof | |
CN110963894B (en) | Andrographolide compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Effective date: 20230915 |